Pharmacological management of type 2 diabetes mellitus in patients with CKD

Journal of Renal Care
Catherine A Hamilton

Abstract

Effective and appropriate control of blood glucose can significantly reduce the risk of diabetic complications and all-cause mortality in patients with diabetes mellitus and recent years have seen a number of new anti-diabetic medications marketed. However, approximately 30% of patients with diabetes mellitus develop progressive chronic kidney disease (CKD) limiting the selection of agents that can safely be used. Whilst older agents such as metformin and the sulphonylureas remain the mainstay of initial treatment, the elimination and adverse effects profile of a number of these drugs can be a concern in patients with CKD. Additionally, use of the newer agents is often limited by a lack of long-term safety data, particularly in this patient group. Treatment guidelines for anti-diabetic therapy rarely consider safe and efficacious management of those patients with CKD.

References

Oct 1, 1994·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·C R Sirtori, C Pasik
Feb 1, 1996·Clinical Pharmacokinetics·T Salvatore, D Giugliano
May 30, 2006·Diabetes·Ravi RetnakaranUNKNOWN UKPDS Study Group
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
May 21, 2010·Diabetes Care·Diana SherifaliHertzel C Gerstein

❮ Previous
Next ❯

Citations

Sep 16, 2014·Journal of Renal Care·Eric Wombwell, Andrew Naglich
Sep 25, 2012·Orvosi hetilap·Zoltán Balogh, János Mátyus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.